Federal R&D programs speed up small-business innovation timelines
H.R. 3239 — Research Advancing to Market Production for Innovators Act · Filed by Chrissy Houlahan (D-PA) · 2 cosponsors · Introduced May 7, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs to accelerate commercialization of federally-funded research. It shortens Phase I award timelines from 1 year to 180 days, requires peer reviewers to assess commercialization likelihood alongside scientific merit, mandates each federal agency designate a Technology Commercialization Official, expands technical and business assistance funding (up to $6,500 for Phase I, $50,000 for Phase II), enables participation in Innovation Corps training, and creates an annual commercialization impact assessment. Small businesses and researchers benefit through faster funding cycles, better commercialization guidance, and expanded support services.
Why we flagged it
The bill's core mechanism is procedural and programmatic reform of existing federal R&D programs (SBIR/STTR) to reduce friction and expand commercialization support. It is not a tax measure, appropriation, or deregulation—it is a targeted improvement to how federal agencies manage innovation grants.
What the text implies
- Commercialization-focused peer review may inadvertently deprioritize high-risk, high-reward basic research in favor of near-term market applications, potentially narrowing the scope of federally-funded innovation.
- The 180-day Phase I timeline compression may disadvantage researchers in fields requiring longer feasibility studies (e.g., biotech, materials science) relative to software/IT sectors.
- Mandatory Technology Commercialization Officials add administrative overhead to federal agencies; effectiveness depends on hiring qualified personnel and may strain smaller agency SBIR programs.
- The commercialization impact assessment (9-year lookback on 50+ Phase II awardees) creates a high bar for measurement; most small businesses will not appear in the dataset, limiting visibility into program-wide outcomes.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
The bill removes procedural barriers and expands support services for small businesses commercializing federally-funded research, accelerating innovation-to-market timelines and reducing administrative friction. The primary beneficiaries are small business innovators and researchers, whose access to federal R&D funding and commercialization support is enhanced; the public benefits indirectly through faster technology deployment and economic growth.
Who stands to gain
- Small business innovation firms (SBIR/STTR awardees)
- Technical and business assistance vendors (consulting, IP, cybersecurity services)
- Innovation Corps (I-Corps) program providers
- Patent examination services (USPTO)
Named in the bill
Small Business Administration (SBA), Small Business Innovation Research (SBIR) program, Small Business Technology Transfer (STTR) program, National Institutes of Health (NIH), Department of Defense (DoD), Department of Education (ED), Innovation Corps (I-Corps), United States Patent and Trademark Office (USPTO), House Committee on Small Business, Senate Committee on Small Business and Entrepreneurship
Where it stands
2 cosponsors: 2 Republicans.
- May 7, 2025 — Introduced · Congress.gov: “Introduced in House”
- May 7, 2025 — Referred to House Committee on the Judiciary and House Committee on Science, Space, and Technology · Congress.gov: “Referred to the Committee on Small Business, and in addition to the Committees on Science, Space, and…”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
1 lobbying clients named this bill on 2 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $60,000 in lobbying spend. A filing names 9 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 0% of bills with at least one filing.
Chrissy Houlahan, the sponsor, reported $573,000 in PAC receipts in the 2026 cycle.
- National Veteran Small Business Coalition — $60,000 on 2 filings
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (11,661 characters) on Nov 2, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,927 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Dec 2025 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-11-02.
“Federal R&D programs speed up small-business innovation timelines” QuorumCivic. https://share.quorumcivic.app/bill/119/hr3239 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.